Results 61 to 70 of about 7,728 (235)

Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction

Acta Dermato-Venereologica, 2021
Chronic nodular prurigo is characterized by recalcitrant itch. Patient perspectives on therapeutic goals, satisfaction with therapy and efficacy of therapeutic regimens for this condition are unknown. This questionnaire study examined these issues in 406
Manuel P. Pereira, Claudia Zeidler, Joanna Wallengren, Jon Anders Halvorsen, Elke Weisshaar, Simone Garcovich, Laurent Misery, Emilie Brenaut, Ekin Şavk, Nikolay Potekaev, Andrey Lvov, Svetlana Bobko, Jacek C. Szepietowski, Adam Reich, Agnieszka Bozek, Franz J. Legat, Martin Metz, Markus Streit, Esther Serra-Baldrich, Margarida Gonçalo, Michael Storck, Teresa Nau, Vincent Hoffmann, Sabine Steinke, Ina Greiwe, Martin Dugas, Matthias Augustin, Sonja Ständer   +27 more
doaj   +1 more source

Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis [PDF]

, 2023
Shawn G. Kwatra, Danielle Rodriguez, Carla Dias-Barbosa, Ismail Budhiarso, Fatoumata Fofana, Margaret Vernon, Sylvie Gabriel, Christophe Piketty, Jorge Puelles   +8 more
openalex   +1 more source

Bullous prurigo pigmentosa

Open Life Sciences, 2019
AbstractPrurigo pigmentosa (PP) is an inflammatory dermatosis with unknown etiology. The clinical presentations of PP varies according to the stages of the disease. Rarely, the formation of numerous vesicles and bullae upon erythematous infiltrative plaques can be found during the entire clinical course. In the present case, a 29-year-old Chinese woman
Wang Xinjun, Xu Chenchen
openaire   +4 more sources

Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Achieving rapid control of itch in atopic dermatitis and prurigo nodularis may minimize symptomatology and disease burden. Analysis of clinical trials in atopic dermatitis and prurigo nodularis showed significantly more patients in nemolizumab versus placebo groups achieved a meaningful clinical response in itch within 48 h, and separation increased ...
Sonja Ständer, Sarina B. Elmariah, Shawn G. Kwatra, Gil Yosipovitch, Andrew E. Pink, Soo Yeon Cheong, Xiaoxiao Chen, Zarif K. Jabbar‐Lopez, Liliana Ulianov, Christophe Piketty, Jonathan I. Silverberg   +10 more
wiley   +1 more source

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Franz J. Legat, Shawn G. Kwatra, Adam Reich, Serge Boulinguez, Athanasios Tsianakas, Maxwell Sauder, Sebastien Barbarot, Jacek C. Szepietowski, Curdin Conrad, Andrew E. Pink, Elke Weisshaar, Laurent Misery, Martin Metz, Vivian T. Laquer, Raja K. Sivamani, Gil Yosipovitch, Diamant Thaçi, Lone Skov, Xiaoxiao Chen, Aliene Noda, Zarif K. Jabbar‐Lopez, Christophe Piketty, Sonja Ständer   +22 more
wiley   +1 more source

Adénocarcinome de l'ampoule de Vater révélé par un prurigo

The Pan African Medical Journal, 2017
Le prurigo chronique peut être révélateur de plusieurs maladies internes. L’association à une néoplasie solide est rare. Nous rapportons un cas exceptionnel d’un prurigo chronique révélateur d’un adénocarcinome de l’ampoule de Vater, curable ...
Ilhame Naciri, Baderddine Hassam
doaj   +1 more source

Diagnosis and epidemiologic overview of the spectrum of skin diseases in Central, Northeast Ethiopia and Southern Ethiopia

Dermatology Reports
This study analyzed data from hospitals located in three regions of Ethiopia: Addis Ababa, Northeastern Ethiopia, and Southern Ethiopia. The research aims to investigate the prevalence and contributing factors associated with skin diseases in these ...
Sara Rovaris, Paola Monari, Abraham Getachew Kelbore, Takele Tadesse, Efa Ambaw Bogino, Lantesil Wondewosen, Fikirete Getachew, Mehret Techane, Shimelash Bitew, Piergiacomo Calzavara-Pinton, Aldo Morrone   +10 more
doaj   +1 more source

Dupilumab Reduces Pruritus in Twins With Sjögren–Larsson Syndrome

Pediatric Dermatology, EarlyView.
ABSTRACT Sjögren–Larsson Syndrome (SLS), now termed ALDH3A2‐syndromic epidermal differentiation disorder (sEDD), is a rare genetic disorder marked by thickened skin, spasticity, and intellectual disability. Intractable pruritus is a nearly universal and debilitating feature of SLS that remains poorly managed by current therapies. We describe 4‐year‐old
Kennedy Gallagher, Rame Yousif, Kathryn Hummel, Amy S. Paller   +3 more
wiley   +1 more source

Dupilumab for Chronic Prurigo: Case Series on Effectiveness, Safety, and Quality of Life [PDF]

, 2023
Clara Richter, Jürg Hafner, Manuel Schuermann, Matteo Tanadini, Nisia Trisconi, Peter Schmid‐Grendelmeier, Thomas M. Kündig, Mirjam Nägeli, Marie‐Charlotte Brüggen, Carole Guillet   +9 more
openalex   +1 more source

Premixed Lidocaine With Fospropofol Disodium for Safety and Clinical Evaluation Regarding Paresthesia Upon Fospropofol Disodium Injection: A Preclinical Experimental Study and a Randomized Controlled Trial

MedComm, Volume 7, Issue 4, April 2026.
This study explored the effect of lidocaine premixing on fospropofol‐induced paresthesia. While the mixture of fospropofol (FP) and lidocaine (LD) proved chemically stable and safe in preclinical tests, clinical results from randomized controlled trial showed no reduction in paresthesia in FP+LD group compared with FP+NS group.
Bo Jiao, Xiaolin Xu, Ying Cui, Caiyi Yan, Liyun Deng, Dequan Zhong, Qing Yang, Jiqian Xu, Yi Liu, Xiaohui Sun, Mengqian Xu, Tao Liu, Hui Xu, Xuejiao Tang, Xiaoqin Luo, Peng Liang, Jin Liu, Chan Chen   +17 more
wiley   +1 more source